×
About 3,380 results

ALLMedicine™ Mastocytosis Center

Research & Reviews  880 results

Study of Factors Regulating Mast Cell Proliferation
https://clinicaltrials.gov/ct2/show/NCT00044122

Feb 3rd, 2023 - This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number and survival in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving thera...

Brain Nocardiosis Defined by 18F-Fluorocholine PET/CT.
https://doi.org/10.1097/RLU.0000000000004564
Clinical Nuclear Medicine; García Vicente AM, Noriega Álvarez E et. al.

Feb 3rd, 2023 - Nocardia infection (nocardiosis) is usually acquired by inhalation; so pulmonary nocardiosis is the most common clinical presentation. Extrapulmonary localization occurs through hematogenous dissemination or contiguous spread. Nocardia can involve...

Updates in diagnosis and management of paediatric mastocytosis.
https://doi.org/10.1097/ACI.0000000000000869
Current Opinion in Allergy and Clinical Immunology; Tiano R, Krase IZ et. al.

Feb 3rd, 2023 - Paediatric mastocytosis is a rare clonal disorder characterized by the overproduction and organ infiltration of mast cells. Symptoms are due to mast cell mediator release. Cutaneous mastocytosis is the most common presentation in children with sys...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Comprehensive mastocytosis data analysis from a single center.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875486
BMC Cancer; Tiryaki TO, Özkan SG et. al.

Jan 25th, 2023 - Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wi...

see more →

Guidelines  3 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of t...
https://doi.org/10.1111/all.12436
Allergy Valent P, Escribano L et. al.

May 20th, 2014 - Mastocytosis is an emerging differential diagnosis in patients with more or less specific mediator-related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, ho...

Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and ...
https://doi.org/10.1111/j.1365-2222.2011.03788.x
Clinical and Experimental Allergy : Journal of the Britis... Krishna MT, Ewan PW et. al.

Aug 19th, 2011 - This guidance for the management of patients with hymenoptera venom allergy has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

see more →

Drugs  263 results see all →

Clinicaltrials.gov  70 results

Study of Factors Regulating Mast Cell Proliferation
https://clinicaltrials.gov/ct2/show/NCT00044122

Feb 3rd, 2023 - This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number and survival in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving thera...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

Jan 19th, 2023 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
https://clinicaltrials.gov/ct2/show/NCT02561988

Jan 13th, 2023 - This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered orally (PO), in adult...

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT05186753

Jan 11th, 2023 - This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of CGT9486 plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdv...

see more →

News  129 results

Mastocytosis: Rare, underdiagnosed, potentially fatal
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD

Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.

Cutaneous Manifestations in Hereditary Alpha Tryptasemia
https://www.mdedge.com/dermatology/article/260439/contact-dermatitis/cutaneous-manifestations-hereditary-alpha-tryptasemia
Allison Kranyak, MD, Marshall Shuler, MD et. al.

Jan 3rd, 2023 - Hereditary alpha tryptasemia (HaT), an autosomal-dominant disorder of tryptase overproduction, was first described in 2014 by Lyons et al. 1 It has been associated with multiple dermatologic, allergic, gastrointestinal (GI) tract, neuropsychiatric,.

Incidental skin finding
https://www.mdedge.com/familymedicine/article/260254/dermatology/incidental-skin-finding
MDedge Family Medicine;

Dec 19th, 2022 - This patient was given a diagnosis of cutaneous mastocytosis. The condition was previously known as urticaria pigmentosa, but in 2016 the World Health Organization reclassified the disease to better suit its pathophysiology as a myeloid cell disor.

Itchy Red-Brown Spots on a Child
https://www.mdedge.com/dermatology/article/259129/pediatrics/itchy-red-brown-spots-child
Deniz Demircioǧlu Duman, MD, Emel Öztürk Durmaz, MD

Nov 1st, 2022 - The Diagnosis: Maculopapular Cutaneous Mastocytosis (Urticaria Pigmentosa) A stroke test revealed urtication at the exact traumatized site (Figure). A skin biopsy performed 2 years prior by another physician in the same hospital had revealed mast.

Myeloma Risk in 9/11 Workers; New Ibrutinib Indication; Help for Chemo Brain?
https://www.medpagetoday.com/hematologyoncology/othercancers/100416

Aug 26th, 2022 - More evidence that first responders and clean-up crews at the site of the World Trade Center continue to have a heightened risk for multiple myeloma and the precursor condition monoclonal gammopathy of uncertain significance. (Sylvester Cancer Cen...

see more →

Patient Education  7 results see all →